Washington · 86362

Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody in Washington

Washington Medicare Avg
$11.81
0% above national avg
National Medicare Avg
$11.80
All states combined
Billed Charge (WA)
$738.58
What providers submit
Est. Commercial (WA)
$27.75
National avg: $26.43
Est. Cash / Self-Pay (WA)
$211.97
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

16
Services in WA
3
Providers
N/A
Min Payment
N/A
Max Payment

Washington Pricing in Context

In Washington, CPT code 86362 (Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody) carries an average Medicare payment of $11.81 — 0% above the national benchmark of $11.80. 3 providers across the state submitted claims for this procedure in 2023, performing 16 total services. Individual payments in WA ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Washington is $738.58, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Washington sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Immunology procedures, the estimated commercial insurance price in Washington lands near $27.75, with self-pay cash prices typically around $211.97. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody cost in Washington?

The average Medicare payment for Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody in Washington is $11.81, which is 0% above the national average of $11.80. Providers in WA typically bill $738.58 for this procedure.

What does Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody cost with insurance in Washington?

With commercial insurance in Washington, Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody costs an estimated $27.75. Without insurance, the estimated cash price is $211.97. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody in Washington?

3 providers in Washington billed Medicare for Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody in 2023, performing 16 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody cheaper in Washington than the national average?

No — Cell-Based Immunofluorescence (cba) Detection Of Myelin Oligodendrocyte Glycoprotein (mog-Igg1) Antibody costs 0% above the national average in Washington. The state average Medicare payment is $11.81 compared to $11.80 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial